Three Houston-based health tech companies were announced to have joined the 2022 cohort of MedTech Innovator. Photo via Getty Images

Three Houston-based medtech startups are getting a big boost from a medtech accelerator.

The startups — Ad Vital, Corveus Medical, and CorInnova — have been chosen from this year’s cohort for MedTech Innovator, an international accelerator that helps companies that created health care technology. In all, 55 startups are involved in this year’s four-month accelerator program.

Ad Vital and Corveus Medical also are participating in MedTech Innovator’s corporate mentorship program, while CorInnova is one of five startups picked for the pediatric accelerator track.

MedTech Innovator’s 10th annual program kicked off in mid-June at the MedTech Innovator Summit in Mountain View, California. Leaders from each of the 50 startups attended networking events and workshops with MedTech Innovator partners and other industry professionals. Members of this year’s cohort also were featured June 17 at the WSGR Medical Device Conference in San Francisco.

Only 5 percent of applicants were accepted for this year’s accelerator program. Earlier this year, MedTech Innovator held in-person pitch events in five cities, including Houston.

At the conclusion of the 2022 program, MedTech Innovator will award $500,000 in cash and in-kind prizes at this October’s MedTech Conference in Boston. The grand prize is $350,000.

“Over the past nine years, MedTech Innovator has established a unique track record of identifying and supporting leading startups, with 95 percent of our graduates either still in business or having been acquired,” Paul Grand, CEO of MedTech Innovator, says in a news release.

Here’s an overview of what Ad Vital, Corveus Medical, and CorInnova do:

  • Ad Vital’s app helps medical practices through sales, marketing, and operations. For instance, the app automatically organizes sales campaigns aimed at converting customer leads via text messages, emails, and Facebook messages.
  • Corveus Medical’s catheter device is designed to prevent heart failure. More than 6 million American adults experience heart failure. The company is also among five selected to pitch in October for a competition from the National Capital Consortium for Pediatric Device Innovation.
  • CorInnova’s minimally invasive device is engineered to treat congestive heart failure, particularly infants. Each year, about 10,000 babies born in the U.S. have critical heart defects that often require surgery or other procedures.
Houston-based CorInnova is gearing up to pitch at a prestigious event. Photo via CorInnova.com

Houston health tech company tapped for prestigious pediatric medical device competition

ready to pitch

Houston-based medtech company CorInnova is gearing up for what could be a big payday.

CorInnova is among five medtech companies that have been invited to present pitches in October for the National Capital Consortium for Pediatric Device Innovation’s “Make Your Medical Device Pitch for Kids!” competition.

CorInnova and the four other finalists now have access to a four-month pediatric accelerator program led by MedTech Innovator and will vie for a share of $150,000 in grant funding from the U.S. Food and Drug Administration (FDA). The pitch event is part of the 10th annual Symposium on Pediatric Device Innovation.

“Addressing unmet needs across pediatric populations is critical to advancing children’s health, and we are delighted to once again work with pioneering companies that seek to bridge this care gap,” says Kolaeh Eskandanian, president and chief innovation officer at Children’s National Hospital and principal investigator for the pediatric device consortium.

CorInnova has developed a minimally invasive device for the treatment of congestive heart failure. Specifically, CorInnova’s soft, flexible device can be inserted through a 1-inch incision to increase the amount of blood pumping in the heart by 50 percent.

The device’s primary benefit is that there’s no contact with blood, thus minimizing complications when the device is being used. Blood contact during a heart procedure can increase the risk of health problems such as stroke and kidney disfunction.

“The device is collapsible, allowing it to be delivered and secured to the heart in a minimally invasive manner. The device conforms to the heart’s surface, and gently compresses the heart to increase cardiac output using an external pneumatic driver that operates in synchrony with the heartbeat,” CorInnova explains on its website.

In the U.S., around 40,000 babies are born each year with congenital heart defects. About one-fourth of these newborns have critical defects, often prompting the need for surgery or other procedures.

Since being founded in 2004, CorInnova has raised at least $6.3 million, according to Crunchbase. This includes a $6.1 million investment from Wellcome Trust, a London-based charitable foundation that focuses on biomedical research.

Aside from the MedTech Innovator accelerator, CorInnova has participated in the TMC Accelerator’s fall 2019 accelerator program for medical device makers and the fall 2018 gBETA Medtech accelerator program.

The four other finalists in the medtech pitch competition are:

  • La Palma, California-based Innovation Lab, whose mechanical elbow brace stabilizes tremors in some pediatric patients with cerebral palsy.
  • Biddeford, Maine-based Prapela, whose vibrating pad helps treat apnea in newborns.
  • Richmond, Virginia-based Tympanogen, whose nonsurgical procedure takes the place of surgery for eardrum repair.
  • Xpan of Concord, Ontario, Canada, whose universal trocar (a surgical instrument) improves safety, access, and flexibility during various procedures.
The Houston Angel Network's investors heard from growing startups in their portfolio — along with a few prospects. Getty Images

11 startups pitch top Houston angel investors at biannual summit

money moves

The Houston Angel Network checked in with their investors and portfolio companies at their biannual Houston Angel Summit that gathered HAN members, local investors, and startup founders for a day full of educational opportunities, pitches, and fireside chats.

The event, which took place last week at Rice University's Liu Idea Lab for Innovation and Entrepreneurship, featured 11 startups – both new and more familiar to HAN members – pitching their growing companies in hopes of catching the interest of potential investors.

BioMedical Music Solutions

Austin-based BioMedical Music Solutions has a SaaS platform that uses artificial intelligence and music to accelerate rehabilitation at a lower cost. Founder Hope Young explained her years-proven therapy can work its magic in one-third of the time and one-tenth of the cost of traditional physical therapy sessions.

Optelos

Houston-based Optelos has a patented SaaS solution that can transform physical asset images, videos, and documents into what's known as a "Digital Inspection Twin" that can enabling knowledge workers utilizing our unified data management, reality modeling, and in-process artificial intelligence solution, to digitally visualize, analyze and manage their entire asset base.

Pocket Naloxone

Maryland-based Pocket Naloxone is attempting to solve the opioid crisis. The company has a portfolio of over-the-counter drug overdose reversal agents, including a naloxone OTC product.

AI Driller

Houston-based AI Driller is using mathematic algorithms to apply automation on rigs for drilling. The startup can also offer its clients real-time data and cuts out the opportunity for human error.

Cavu Biotherapies

Houston pet immunotherapy company, Cavu Biotherapies, has seen a tremendous amount of growth and is now a treatment partner at 43 clinic providers in 18 states and Canada. Founder Colleen O'Connor says she's seen a near 600 percent growth in revenue over the past year and treated 38 dog cancer patients in that timeframe.

CorInnova

Another Houston company, CorInnova, has created a device from a soft, flexible material that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping in the heart by 50 percent.

Hive Genie

Houston-based Hive Genie is using technology to help beekeepers optimize their pollination operations and monitor hive operations remotely. Gone are the days, Hive Genie hopes, that beekeepers need to suit up to track and maintain their colonies physically.

Siera AI

Austin-based Siera AI is using its AI-enabled cloud IoT platform for logistics solutions and safety improvements in warehouse settings. A goal of the company's, according to its website, is to free humans from these types of dull, dangerous, dirty tasks.

Skycom

The sky's not even the limit for Austin-based Skycom and its airship technology that supplies low-cost cell towers in orbit. The technology can bring down the cost of mobile service providers and allow for growth into new markets.

Tevido

Another Austin company, Tevido uses a pigment cell graft process to use patients' own skin cells to restore normal skin color for patients with vitiligo and pale scars.

Tot Squad

Los Angeles-based Tot Squad emerged as a service-focused company for baby-related tasks and now has emerged as a digital marketplace connecting service providers online to parents and to-be parents for needs like stroller cleaning or carseat installation.

Four Houston companies showed the city what they're made of at TMCx's recent Demo Day. Courtesy of TMCx

Houston-based medical device companies pitch at TMCx Demo Day

Local legends

Earlier this month, 16 medical device companies wrapped up their time at the Texas Medical Center's accelerator program and pitched their companies to fellow health professionals, guests, and more. While each made important connections in the local ecosystem during the program, a quarter of the entrepreneurs had roots in Houston already.

Four of the 16 TMCx09 companies that are headquartered in Houston. They have built solutions within sepsis, surgery, and transplant spaces in health care. Here's a little more about the homegrown companies that pitched at the event.

CorInnova

Photo via corinnova.com

The standard practice for acute heart failure patients is very invasive, says William Altman, CEO of CorInnova.

"The problem with existing devices is that they have invasive blood contact," Altman says. "Problem with that is blood contact is bad. It can cause up to 15 percent rate of stroke, which could kill you, and after five to seven days it provides 10 percent rate of blood destruction and has a 47 percent rate of kidney disfunction."

CorInnova's technology features a device that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping by 50 percent.

"Surgeons tell us this is less invasive than minimally invasive aortic valve replacement, which is a widely done surgery, so this promises widespread adoption for our technology as we get it approved," Altman says.

The human prototype is expected to be ready in two years, with the next year being focused on animal studies. CorInnova is raising $12 million to accomplish its goals.

Ictero Medical

Getty Images

An estimated 10 to 15 percent of the United States population will get a gallstone in their lifetime. Should one of those stones cause trouble or blockages, the only solution is to remove the gallbladder completely through surgery. However, Matthew Nojoomi, CEO and co-founder of Ictero Medical, has another idea.

Ictero Medical has created a minimally invasive treatment that uses cryoablation to defunctionize the gallbladder without having to remove it.

"The CholeSafe System not only treats the source of the disease, but it leverages existing clinical workflows that doctors use to access the gallbladder," says Nojoomi, adding that the process only uses mild station and pain control.

The company expects to get to humans in the next two years, and has launched a financing round.

PATH EX

path ex

Photo via tmc.com

Currently, sepsis is hard to identify in patience. Even if a patient is in a hospital, and that hospital knows the patient has sepsis, the individual still has a 38 percent chance of dying, says Sinead Miller, CEO of PATH EX.

"Right now the problems associated with sepsis are very clear," she says. "It's the leading cause of death in our ICUs, and it's also associated with the highest hospital cost and readmission rates."

PATH EX's technology allows medical professionals to better diagnose and treat sepsis. The PATH EX therapeutic device can be hooked up to a patient and flow his or her blood through the machine to capture bacteria, clean and recirculate the blood, and faster diagnose what sort of bacteria the patient has attracted. The device technology is similar to hemo hemodialysis, Miller explains.

The Houston company, which recently won big at the Ignite Healthcare Network's Fire Pitch Competition, was named an honoree within the Johnson and Johnson Breakthrough Medical Technologies Quickfire Challenge.

The company was recently received clearance from the Food and Drug Administration as a breakthrough device technology. PATH EX closed its $615,000 seed round — with plans for a series A next year — and has received $1 million in SBIR grant funding. The company was founded two years ago, and relocated to call Houston HQ this year.

Volumetric

Jordan Miller/Rice University

Volumetric is banking on their technology being among the inventions that will lead the medical industry into the future. The human tissue-printing technology company has created the 3D printer and the "ink" that can create whole organs for transplant.

"We can create complicated vascular architectures inside of soft water-based gels, in this case, mimicking the structure and function of human lung tissue," says Jordan Miller, CEO. "We can oxygenate red blood cells."

The company is commercializing its technology and has three streams of revenue, which as generated almost $1 million in revenue in Volumetric's second year. The company is also in the process of closing its seed round of fundraising.

Earlier this year, the startup, which works out of Rice University, was featured on the cover of Science magazine.

Here's what life science startups were named most promising at the recent Rice Alliance Texas Life Science Forum.. Getty Images

Rice Alliance names most promising life science companies at annual forum

Best of the best

Houston hosted an annual meeting of the minds that included thoughtful discussions, presentations, panels, and startup pitches within the life science industry.

The Texas Life Science Forum, organized and hosted by the Rice Alliance and BioHouston, took place on November 6 at Rice University's Bioscience Research Collaborative. Throughout the day, over 50 life science startups pitched to the audience. At the end of the forum, 10 startups — most of which are based in Houston — were recognized as being the most promising.

Here's what life science startups you should be keeping an eye out for.

Abilitech Medical

abilitech

Photo via abilitechmedical.com

A St. Paul, Minnisota-based medical device company, Abilitech Medical develops assistive technology to Multiple sclerosis, Muscular Dystrophy, Parkinson's and stroke patients. The first product, Alibitech Assist, will be cleared by the FDA in 2020, with other devices to follow in 2022 and 2023.

AgilVax

agilvax

Photo via agilvax.com

Based in Albuquerque, New Mexico, AgilVax is a biopharmaceutical company that works with chemotherapy, checkpoint and KRAS inhibitors to fight various cancers. The company's AX09 is an immunotherapeutic that is headed for human clinical trials in 2020. Another product, M5, is a monoclonal antibody currently in preclinical trials.

Altoida

altoida

Photo via altoida.com

Altoida, based in Houston, has created a medical device that uses artificial intelligence and augmented reality to collect functional and cognitive data in patients to determine their risk Mild Cognitive Impairment from Alzheimer's Disease. The Altoida Neuro Motor Index has been cleared by the FDA and CE and detects cognitive decline with a 94 percent diagnostic accuracy six to 10 years ahead of the onset of symptoms.

ColubrisMX

Photo via Pexels

Houston-based ColubrisMX makes surgical robots specializing in minimally invasive and endoluminal surgeries. The company's team of engineers and surgeons works adjacent to the Texas Medical Center.

Cord Blood Plus

stem cell

Photo via Getty Images

Cord Blood Plus, based in Galveston, is working to commercialize its human umbilical cord blood stem cell technology. The company's primary mission is to use its research and treatment on breast cancer patients undergoing chemotherapy in order to prevent infections, speed up recovery, and shorten hospital stays.

CorInnova

CorInnova

Photo via CorInnova.com

Another Houston company, CorInnova is a medical device company that has developed a cardiac assist device to treat heart failure without many of the consequences from standard treatment. The device is able to self expand and gently compress the heart in sync with the heartbeat.

Mesogen

mesogen

Photo via Mesogen.com

Mesogen, which is based in The Woodlands, is in the business of using a patient's own cells to grow a human kidney for transplant. The tissue engineering technology allows for the creation of a kidney in less than a year with less risk of transplant rejection and a better quality of life over dialysis treatment.

Saranas

Courtesy of Saranas

Houston-based Saranas has created its Early Bird device to more quickly and more accurately detect bleeding in the human body. The company, which underwent successful clinical trials last year, recently received FDA clearance and launched the device in the United States.

Stream Biomedical

stream biomedical

Photo via streambiomedical.com

Stream Biomedical Inc. is tapping into a therapeutic protein that has proven to be neuroprotective and neuroreparative. The Houston company is aiming to apply the treatment in acute stroke cases and later for traumatic brain injury, Alzheimer's, and dementia cases.

VenoStent

Photo via venostent.com

Houston-based VenoStent has created a device that allows a successful stent implementation on the first try. VenoStent's SelfWrap is made from a shape-memory polymer that uses body heat to mold the stent into the vein-artery junction.

The next TMCx cohort begins August 5. Courtesy of TMC

TMCx announces its next medical device cohort with 5 startups hailing from Houston

Health tech

The Texas Medical Center's startup accelerator, TMCx, has added 19 companies from all around the world to join its medical device family.

The TMC Innovation Institute team narrowed down 140 applications to 40 for the second round of the process, which includes face-to-face interviews, according to a release. After those, 18 companies were selected to join the TMCx09 class, which focuses on medical devices. The last cohort, which specialized in digital health, concluded on June 6.

Out of the 18 companies, five are from Houston. Four other startups hail from other corners of the United States, while 10 international companies also made the cohort. The program commences on August 5, and will run for four months before concluding in a demo day event in November.

Here are the medical device startup companies joining the TMCx09 cohort.

See update at the bottom of this story.

Vascular devices

  • Neurescue (Copenhagen, Denmark) — Neurescue has developed a computer-aided aortic occlusion catheter to help save the lives of patients in the emergency care setting.
  • Venari Medical (Galway, Ireland) — Venari Medical is developing BioVena — a medical device that treats varicose veins and venous leg ulcers with a minimally invasive approach intended to reduce pain.
  • Obsidio (Solana Beach, California) — Obsidio is developing a universal gel embolic material to shrink lesions or to treat internal bleeds, aneurysms and vascular malformations.

Novel therapies

  • PATH EX (Houston) — PATH EX is developing an extracorporeal blood cleansing device designed to selectively remove pathogens, including multi-drug resistant bacteria, and endotoxins from circulating blood to diagnose and treat sepsis.
  • Innosphere (Hafia, Israel) — Innosphere is a medical device company developing brain stimulation solutions for treating cognitive disorders, with a focus on ADHD.

Rehab

  • AbiliTech (St. Paul, Minnesota) — AbiliTech is restoring independence to patients with upper limb neuromuscular conditions by offering a wearable assistive device that allows the user to perform independent activities of daily living.
  • Komodo OpenLab (Toronto, Ontario, Canada) — Komodo OpenLab has developed Tecla, an assistive device giving individuals with physical disabilities the ability to communicate, control, and connect with the world.

Surgery

  • CNX Medical (Houston) — CNX Medical is developing a transcutaneous neurostimulator that is placed in the ear and helps reduce inflammation after abdominal surgery, with a focus on post-operative ileus.
  • CorInnova (Houston) — CorInnova has developed a soft robotic non-blood contacting biventricular cardiac assist device for the treatment of heart failure that would eliminate the many adverse events associated with current technologies.
  • Ictero Medical (Houston) — Ictero Medical is developing a minimally invasive ablation solution to treat high-risk patients with gallstone disease and offer patients the benefits of surgery without the risk. The company was among the big winners at the Texas A&M New Ventures Competition.

Diagnostics

  • Artidis (Basel, Switzerland) — InArtidis has developed a nanomechanical biomarker technology using precise tissue measurement in combination with data analytics to personalize cancer diagnosis.
  • Inveox (Munich, Germany) — Inveox automates the pre-analytical process in cancer diagnosis to improve patient safety and lab efficiency.
  • Cambridge Respiratory Innovations Ltd. (Cambridge, United Kingdom) — CRiL has developed, N-Tidal, a device that analyzes CO2 end-tidal breathing to improve respiration monitoring.

Toward home health

  • Kegg (San Francisco) — Kegg is on a mission to simplify every woman's journey towards taking charge of her fertility with a user-friendly monitoring device.
  • TestCard (London) — TestCard is a flat pack urine test kit that functions in combination with a mobile phone application, turning a phone's camera into a clinical grade scanner.
  • Patch'd (New South Wales, Australia, and San Francisco) — Patch'd uses deep learning and wearable devices to predict the onset of sepsis in the at-home patient.

Transplant

  • Volumetric (Houston) — Volumetric's 3D bioprinting platform creates materials with living cells with applications in biomaterials, cancer research, and eventually human organ replacements. The company's technology started out of Rice University.
  • Tevosol (Edmonton, Alberta, Canada) — Tevasol is developing organ transplant transportation solutions. Their portable warm perfusion machines will help surgeons transplant more organs today and solve organ shortage tomorrow.

------

Diagnostic Photonics withdrew from the program after the article published.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Deadline extended: InnovationMap, HX open nominations for new combined awards gala

calling all innovators

Update: The deadline for nominations have been extended to midnight on Sunday, October 2.

InnovationMap is back to honor local startups and innovators — and this time, we've upped the ante.

Houston Exponential and InnovationMap have teamed up to combine their annual awards and event efforts to premiere a brand new program. The Houston Innovation Awards Gala on Wednesday, November 9, at The Ion will be a comprehensive event honoring Houston founders, innovators, investors, and more. InnovationMap and HX, which was acquired earlier this year, are in the same network of ownership.

Nominations are open online until midnight October 2, and nominees will have until October 11 to complete an additional application that will be emailed to nominees directly. A group of industry experts and Houston innovation leaders will review those submissions and determine finalists and winners across 11 categories. The categories for this year's awards are:

  • BIPOC-Owned Business honoring an innovative company founded or co-founded by BIPOC representation
  • Female-Owned Business honoring an innovative company founded or co-founded by a woman
  • Hardtech Business honoring an innovative company developing and commercializing a physical technology across life science, energy, space, and beyond
  • B2B Software Business honoring an innovative company developing and programming a digital solution to impact the business sector
  • Green Impact Business honoring an innovative company providing a solution within renewables, climatetech, clean energy, alternative materials, and beyond
  • Smart City Business honoring an innovative company providing a tech solution within transportation, infrastructure, data, and beyond
  • New to Hou honoring an innovative company, accelerator, or investor that has relocated its primary operations to Houston within the past three years
  • DEI Champion honoring an individual who is leading impactful diversity, equity, and inclusion initiatives and progress within Houston and their organization
  • Investor of the Year honoring an individual who is leading venture capital or angel investing
  • Mentor of the Year honoring an individual who dedicates their time and expertise to guide and support to budding entrepreneurs
  • People's Choice: Startup of the Year selected via an interactive voting portal during of the event
Nominees can be submitted to multiple categories.

Additionally, the awards gala will honor an innovator who's made a lasting impact on the Houston innovation community. While you may nominate an individual for the Trailblazer Award via the online form, the judging committee will not require applications or nominations for this category and will be considering potential honorees from the ecosystem at large. If you are interested in sponsorship opportunities, please reach out to cbuckner@houstonexponential.org.

Last year, InnovationMap introduced its awards program and named 28 finalists and honored the nine winners on September 8. Click here to see more from last year's event.

Tickets for the November 9 event are available online. Early bird tickets will be $60 per person and startup founders will be able to attend for $25.

Click here to submit a nomination or see form below.


Major corporation opens hub for global decarbonization in Houston

seeing green

Management consulting giant McKinsey & Co. plans to spend $100 million over the next decade to pump up Houston’s decarbonization economy.

McKinsey says the initiative will, among other things, focus on:

  • Promoting innovations like carbon capture, utilization, and storage (CCUS) and green hydrogen
  • Revamping business models for carbon-heavy companies
  • Ramping up the community of local startups involved in energy transition
  • Developing talent to work on decarbonization

As part of this program, McKinsey has set up a decarbonization hub in its Houston office, at 609 Main St.

“Decarbonization will lead to a new chapter of economic development, while also addressing a critical problem of climate change,” McKinsey partner Nikhil Ati says.

Global decarbonization efforts over the next three decades will require a $100 trillion investment, according to Utility Dive. Houston, home to 40 percent of publicly traded oil and gas companies, stands to gain a substantial share of that opportunity.

McKinsey’s Houston office has worked for several years on Houston’s energy transition initiatives. For instance, the firm helped produce a study and a whitepaper on energy transition here. The whitepaper outlines Houston’s future as the “epicenter of a global clean hydrogen hub.”

“Texas is the nation’s largest renewable energy producer, home to half of the nation’s hydrogen pipelines, and its companies have unparalleled capabilities in building and operating complex projects,” McKinsey senior partner Filipe Barbosa says. “This is Houston’s moment in time on the global stage.”

McKinsey estimates a Houston-based global hub for clean hydrogen that’s in place by 2050 could generate 180,000 jobs and create an economic impact of $100 billion.

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from photonics to robotics — recently making headlines in Houston innovation.

Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship

Brad Burke joins this week's Houston Innovators Podcast. Photo via alliance.rice.edu

Collaboration has made a world of a difference for growing Houston's innovation ecosystem, according to Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship.

"I think Houston has this culture of collaboration that I suspect that some other major cities don't have in the same way," Burke says on the Houston Innovators Podcast. "And while we're a big city, the entrepreneurial ecosystem feels like a small network of a lot of people who work really well together."

Burke has played a major role in the collaboration of Houston for the past 20 years leading the Rice Alliance, which coordinates many event programs and accelerators — including the Rice Business Plan Competition, energy and life science forums, the Clean Energy Accelerator, Owl Spark, Blue Launch, and more. Click here to read more.

Trevor Best, CEO and co-founder of Syzygy Plasmonics

A new partnership for Houston-based Syzygy will generate 1.2 million tons of clean hydrogen each year in South Korea by 2030. Image via Syzygy

Houston-area energy tech startup Syzygy Plasmonics is part of a new partnership that will develop a fully electric chemical reactor for production of clean hydrogen in South Korea.

The reactor will be installed in the second half of 2023 at Lotte Fine Chemical’s facilities in Ulsan, South Korea. Lotte Fine Chemical, Lotte Chemical, and Sumitomo Corporation of Americas are Syzygy’s partners in this venture.

“Simply improving existing tech isn’t enough to reach the world’s decarbonization goals. Stopping climate change will require industries to reimagine what is possible,” Syzygy co-founder and CEO Trevor Best says in a news release. “Our technology expands the accepted paradigms of chemical engineering. We have demonstrated the ability to replace heat from combustion with renewable electricity in the manufacture of foundational chemicals like hydrogen.” Click here to read more.

Nicolaus Radford, CEO and founder of Nauticus Robotics

Houston-based Nauticus Robotics has hit the public market. Image via LinkedIn

Fresh off its September 13 debut as a publicly traded company, Webster-based Nauticus Robotics Inc. is aiming for $90 million in revenue next year as it dives deeper into the ocean economy.

The stock of Nauticus now trades on the NASDAQ market under the ticker symbol KITT. Nauticus went public following its SPAC (special purpose acquisition company) merger with New York City-based CleanTech Acquisition Corp., a “blank check” company that went public in July 2021 through a $150 million IPO. The SPAC deal was valued at $560 million when it was announced in December.

Nauticus continues to be led by CEO Nicolaus Radford and the current executive team.

“The closing of this business combination represents a pivotal milestone in our company’s history as we take public our pursuit of transforming the ocean robotics industry with autonomous systems,” says Radford, who founded what was known as Houston Mechatronics in 2014. “Not only is the ocean a tremendous economic engine, but it is also the epicenter for building a sustainable future.” Click here to read more.